Dipeptidyl peptidase IV and mortality after an acute heart failure episode

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 2, 2013, Pages 138-142

  Lourenço, Patrícia ^a   Friões, Fernando ^a   Silva, Nuno ^b   Guimarães, João Tiago ^b   Bettencourt, Paulo ^a  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b University of Porto   (Portugal)

Author keywords

dipeptidyl peptidase IV; heart failure; natriuretic paradox; natriuretic peptides

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALS, URBAN; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT DISCHARGE; PILOT PROJECTS; PORTUGAL; RISK FACTORS; SURVIVAL ANALYSIS; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84883263010     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182949673     Document Type: Article

References (32)

1. Lambeir AM, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-294.
2. De Meester I, Korom S, van Damme J, et al. CD26, let it cut or cut it down. Immunol Today. 1999;20:367-375.
3. Vanderheyden M, Vrits C, Verstreken S, et al. B-type natriuretic peptide has a marker of heart failure: New insight from biochemistry and clinical implications. Biomark Med. 2010;4:315-320.
4. Drucker DJ. Dipeptidyl peptidase 4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335-1343.
5. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetology. 2005;48:1168-1172.
6. Vanderheyden M, Bartunek J, Goethals M, et al. Dipeptidyl-peptidase IV and B-type matriuretic peptide. From bench to bedside. Clin Chem Lab Med. 2009;47:248-252.
7. Brandt I, Lambair AM, Ketesslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-serPro form. Clin Chem. 2006;52:82-87.
8. Liang F, O?Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071-1078.
9. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. Des-serine-proline B-type natriuretic peptide (BNP 3-32) in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901.
10. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3?,5?-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49:1114-1119.
11. Lam CS, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007;49:1193-1202.
12. Hawkridge AM, Heublein DM, Bergen HR 3rd, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005; 102:17442-17447.
13. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007;53:866-873.
14. Durinx C, Neels H, Van der Auwera JC, et al. Reference values for plasma dipeptidyl-peptidase activity and their association with other laboratory parameters. Clin Chem Lab Med. 2001;39:155-159.
15. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J. 2008;29:2388-2442.
16. Jax T. Treatment of patients with diabetes with GLP-1 analogues or DPP IV inhibitors: A hot topic for cardiologists? Clin Res Cardiol. 2009;98: 75-79.
17. Addison D, Aguilar D. Diabetes and cardiovascular disease: The potential benefit of incretin-based therapies. Curr Atheroscler Rep. 2011;13:115-122.
18. Ban K, Hui S, Drucker DJ, et al. Cardiovascular consequences of drugs used for the treatment of diabetes: Potential promise of incretin-based therapies. J Am Soc Hypertens. 2009;3:245-249.
19. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like receptor-dependent and -independent pathways. Circulation. 2008;117:2340-2350.
20. Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
21. Okerson T, Yan P, Stonehouse A, et al. Effect of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010; 23:3334-3339.
22. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers I patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286.
23. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide 1 on endothelial function in type 2 diabetes patients with stable coronary disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215.
24. Oeseburg H, de Boer RA, Buikema H, et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010;30:1407-1414.
25. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infacrt size and improved cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-510.
26. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975-983.
27. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide 1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
28. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide 1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694-699.
29. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide 1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100: 824-829.
30. Sulistio M, Carothers C, Mangat M, Lujan M, et al. GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep. 2009;11:93-99.
31. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation. 2004;110:894-896.
32. Iwaki-Egawa S, Watanabe Y, Kikuya Y, et al. Dipeptidyl peptidase IV from human serum: Purification, characterization, and N-terminal amino acid sequence. J Biochem. 1998;124:428-433.